Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 2/20 | 0.53 |
| ▸ | EPHX2 | P34913 | 11/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | P2RX7 | Q99572 | 4/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2J2 | P51589 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16793983 | 0.86 | BTK (0.49) | BTKEPHX2P2RX7 | |
| SCHEMBL16793935 | 0.80 | BTK (0.47) | BTKEPHX2P2RX7CYP2C9CYP2J2 | |
| SCHEMBL16814190 | 0.77 | BTK (0.69) | BTKEPHX2CYP2C9CYP2J2 | |
| SCHEMBL16793564 | 0.75 | BTK (0.53) | BTKEPHX2P2RX7CYP2C9CYP2J2 | |
| SCHEMBL10204025 | 0.72 | SETDB1 (0.43) | EPHX2MEN1KMT2AP2RX7CYP2C9 | |
| SCHEMBL20840178 | 0.71 | NPC1 (0.48) | EPHX2MEN1KMT2AP2RX7CYP2C9 | |
| SCHEMBL540605 | 0.70 | SETDB1 (0.57) | EPHX2MEN1KMT2AP2RX7 | |
| SCHEMBL16794448 | 0.69 | BTK (0.56) | BTKKMT2ASMN1; SMN2L3MBTL1 | |
| SCHEMBL20461159 | 0.69 | BTK (0.56) | BTKKMT2ASMN1; SMN2L3MBTL1 | |
| SCHEMBL16793700 | 0.69 | AAK1 (0.49) | EPHX2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180093973-A1 | BIARYL INHIBITORS OF BRUTON'S TYROSINE KINASE | BIOGEN MA INC. | 2018-04-05 | — | — | US | disclosed |
| US-9809577-B2 | Biaryl inhibitors of Bruton's tyrosine kinase | BIOGEN MA INC. (US) | 2017-11-07 | — | — | US | disclosed |
| US-20160311802-A1 | BIARYL INHIBITORS OF BRUTON'S TYROSINE KINASE | BIOGEN MA INC. | 2016-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180093973-A1 | BIARYL INHIBITORS OF BRUTON'S TYROSINE KINASE | ABL1, BTK, LYN | BTK 2/4885EPHX2 1900/4885MEN1 4232/4885 |
| US-20160311802-A1 | BIARYL INHIBITORS OF BRUTON'S TYROSINE KINASE | ABL1, BTK, LYN | BTK 2/4885EPHX2 1900/4885MEN1 4232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.